Pfizer's Vaccine Candidate PF-07307405 Shows Over 70% Efficacy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 23 2026
0mins
Should l Buy PFE?
Source: Newsfilter
- Vaccine Efficacy: Pfizer's 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 demonstrated an efficacy of 73.2% in individuals aged five and older, significantly reducing the rate of confirmed Lyme disease cases, indicating the vaccine's substantial potential in disease prevention.
- Safety Assessment: The investigational vaccine candidate was well tolerated with no safety concerns identified at the time of analysis, which bolsters confidence for future regulatory submissions and may expedite the vaccine's market introduction.
- Clinical Trial Results: The VALOR trial results indicated an efficacy of 74.8% in season two, not only addressing the clinical need for a Lyme disease vaccine but also potentially enhancing Pfizer's competitiveness in the vaccine market.
- Collaborative Development: The ongoing collaboration agreement between Pfizer and Valneva, initiated in April 2020, aims for Pfizer to exclusively manufacture and commercialize the vaccine upon regulatory approval, further solidifying its leadership position in the vaccine sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.680
Low
24.00
Averages
28.56
High
35.00
Current: 25.680
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer Reports 22% Operational Growth in Q1 Amid Patent Challenges
- Revenue Growth Overview: Pfizer's Q1 revenue saw a modest 2% year-over-year increase, yet the operational growth of 22% from newly launched and acquired products indicates potential in its product pipeline, despite ongoing revenue challenges.
- Patent Risk for Key Drugs: The company's leading drugs, Eliquis and Ibrance, generated a combined $3.2 billion last quarter but are facing imminent patent cliffs, which could further pressure future revenues and impact overall business performance.
- Acquisition Strategy Impact: The acquisition of Seagen for $43 billion has yielded promising results, with Padcev, a cancer treatment, achieving a 39% sales increase to $591 million in Q1, thereby strengthening Pfizer's oncology portfolio and enhancing its market position.
- Investor Sentiment Concerns: Despite Pfizer's low valuation, trading at a forward P/E ratio of just nine, investor interest remains tepid due to uncertainties surrounding future performance, reflected in a mere 4% stock price increase this year, indicating cautious market sentiment regarding its recovery prospects.
See More
Pfizer's Revenue Plummets 38% Amid Patent Challenges
- Significant Revenue Decline: Pfizer's revenue plummeted by 38% from over $101 billion in 2022 to less than $63 billion in 2025, highlighting the substantial challenges faced as demand for COVID-related products wanes.
- Poor Stock Performance: The company's stock has declined approximately 35% over the past five years, reflecting market concerns regarding its growth prospects, particularly as key products approach patent expiration.
- New Product Growth Potential: Despite an overall revenue increase of only 2% year-over-year, Pfizer achieved a notable 22% operational growth from newly launched and acquired products in Q1, with Padcev's sales rising 39% to $591 million, establishing it as a leading oncology drug.
- Investor Caution: Although Pfizer's valuation appears low with a forward P/E ratio of just nine, investor confidence remains shaky due to uncertainties about future performance, resulting in only a 4% increase in stock price this year.
See More
SureNano Science Advances GEP-44 Therapy in Obesity Treatment
- Massive Market Potential: The global GLP-1 market is projected to exceed $200 billion by 2035, with SureNano Science advancing its GEP-44 triple agonist platform aimed at enhancing efficacy and patient adherence, thereby positioning itself in a rapidly growing pharmaceutical market.
- Innovative Therapy Development: GEP-44 demonstrated approximately 15% weight loss in preclinical studies, significantly outperforming traditional GLP-1 drugs at 9%, while avoiding common side effects like nausea, which could enhance long-term patient adherence.
- Delivery Technology Innovation: SureNano Science is exploring oral, sublingual, and intranasal delivery technologies to improve patient accessibility and adherence, a strategy that could create new commercial opportunities within the GLP-1 market.
- Strategic Expansion Opportunities: In addition to its core GLP-1 platform, SureNano Science is evaluating early-stage opportunities related to ibogaine, reflecting its strategic flexibility in diversifying therapeutic areas, potentially providing additional value for future growth.
See More
Pfizer Faces Challenges Yet Remains a Worthy Investment
- Patent Expiration Risk: Pfizer faces significant revenue declines as several blockbuster drugs near patent expiration, leading to a pessimistic market outlook reflected in a stock price drop of over 50% from 2021 highs, indicating investor overreaction to its future prospects.
- Competitive Pressure: Although Pfizer has fallen behind in the GLP-1 weight-loss drug race, it quickly pivoted by acquiring a promising drug candidate, demonstrating its ongoing competitiveness in this market segment.
- Dividend Commitment: Management has committed to maintaining the current dividend level, and since dividends are paid from cash flow rather than earnings, the company can sustain these payments for a while as it aims to return to earnings growth, appealing to aggressive income investors.
- Investment Return Potential: With the stock's sharp decline, investors can enter at a 6.5% dividend yield, which, combined with the potential success of Pfizer's drug pipeline, could yield both robust income and capital appreciation, presenting a compelling investment opportunity.
See More
Pfizer's Stock Drops 50% Yet Remains Attractive for Investors
- Significant Stock Decline: Pfizer's stock has plummeted over 50% since its 2021 peak, primarily due to unmet expectations for COVID vaccine revenues, which has intensified market pessimism regarding its future prospects.
- High Dividend Appeal: Despite facing challenges, Pfizer currently offers a 6.5% dividend yield, providing a stable income source for long-term investors while also laying the groundwork for potential capital appreciation in the future.
- Drug Development Dynamics: Although Pfizer has fallen behind in the GLP-1 weight-loss drug race, it quickly pivoted by acquiring a company with a more promising drug candidate, demonstrating its agility in drug development and potential for future product launches.
- Management Confidence: Pfizer's management has clearly stated its intention to maintain the current dividend level despite pressures on profitability, indicating a commitment to shareholder returns while working to restore growth.
See More
S&P 500 Earnings Accelerate with Strong Performance
- Strong Earnings Performance: This week, over 125 S&P 500 companies reported earnings, with 110 exceeding EPS expectations and 103 showing year-over-year earnings growth, indicating resilience in corporate profitability amid changing economic conditions.
- AMD Leads Tech Sector: Advanced Micro Devices (AMD) reported robust revenue of $10.3 billion and an adjusted EPS of $1.37, driven by a 57% surge in Data Center sales, with a Q2 revenue outlook of $11.2 billion, highlighting strong demand in AI and data processing.
- Disney's Continued Growth: Disney (DIS) reported $25.17 billion in revenue and raised its annual EPS growth target to 12%, reflecting its sustained competitiveness and market demand in the entertainment and media sector.
- Super Micro's Optimistic Outlook: Super Micro Computer (SMCI) reported a challenging start with $10.2 billion in revenue, missing expectations, but significantly raised its 2026 revenue guidance to between $38.9 billion and $40.4 billion, indicating strong anticipated demand for AI computing infrastructure.
See More
Pfizer Reports 22% Operational Growth in Q1 Amid Patent Challenges
- Revenue Growth Overview: Pfizer's Q1 revenue saw a modest 2% year-over-year increase, yet the operational growth of 22% from newly launched and acquired products indicates potential in its product pipeline, despite ongoing revenue challenges.
- Patent Risk for Key Drugs: The company's leading drugs, Eliquis and Ibrance, generated a combined $3.2 billion last quarter but are facing imminent patent cliffs, which could further pressure future revenues and impact overall business performance.
- Acquisition Strategy Impact: The acquisition of Seagen for $43 billion has yielded promising results, with Padcev, a cancer treatment, achieving a 39% sales increase to $591 million in Q1, thereby strengthening Pfizer's oncology portfolio and enhancing its market position.
- Investor Sentiment Concerns: Despite Pfizer's low valuation, trading at a forward P/E ratio of just nine, investor interest remains tepid due to uncertainties surrounding future performance, reflected in a mere 4% stock price increase this year, indicating cautious market sentiment regarding its recovery prospects.
See More
Pfizer's Revenue Plummets 38% Amid Patent Challenges
- Significant Revenue Decline: Pfizer's revenue plummeted by 38% from over $101 billion in 2022 to less than $63 billion in 2025, highlighting the substantial challenges faced as demand for COVID-related products wanes.
- Poor Stock Performance: The company's stock has declined approximately 35% over the past five years, reflecting market concerns regarding its growth prospects, particularly as key products approach patent expiration.
- New Product Growth Potential: Despite an overall revenue increase of only 2% year-over-year, Pfizer achieved a notable 22% operational growth from newly launched and acquired products in Q1, with Padcev's sales rising 39% to $591 million, establishing it as a leading oncology drug.
- Investor Caution: Although Pfizer's valuation appears low with a forward P/E ratio of just nine, investor confidence remains shaky due to uncertainties about future performance, resulting in only a 4% increase in stock price this year.
See More
SureNano Science Advances GEP-44 Therapy in Obesity Treatment
- Massive Market Potential: The global GLP-1 market is projected to exceed $200 billion by 2035, with SureNano Science advancing its GEP-44 triple agonist platform aimed at enhancing efficacy and patient adherence, thereby positioning itself in a rapidly growing pharmaceutical market.
- Innovative Therapy Development: GEP-44 demonstrated approximately 15% weight loss in preclinical studies, significantly outperforming traditional GLP-1 drugs at 9%, while avoiding common side effects like nausea, which could enhance long-term patient adherence.
- Delivery Technology Innovation: SureNano Science is exploring oral, sublingual, and intranasal delivery technologies to improve patient accessibility and adherence, a strategy that could create new commercial opportunities within the GLP-1 market.
- Strategic Expansion Opportunities: In addition to its core GLP-1 platform, SureNano Science is evaluating early-stage opportunities related to ibogaine, reflecting its strategic flexibility in diversifying therapeutic areas, potentially providing additional value for future growth.
See More
Pfizer Faces Challenges Yet Remains a Worthy Investment
- Patent Expiration Risk: Pfizer faces significant revenue declines as several blockbuster drugs near patent expiration, leading to a pessimistic market outlook reflected in a stock price drop of over 50% from 2021 highs, indicating investor overreaction to its future prospects.
- Competitive Pressure: Although Pfizer has fallen behind in the GLP-1 weight-loss drug race, it quickly pivoted by acquiring a promising drug candidate, demonstrating its ongoing competitiveness in this market segment.
- Dividend Commitment: Management has committed to maintaining the current dividend level, and since dividends are paid from cash flow rather than earnings, the company can sustain these payments for a while as it aims to return to earnings growth, appealing to aggressive income investors.
- Investment Return Potential: With the stock's sharp decline, investors can enter at a 6.5% dividend yield, which, combined with the potential success of Pfizer's drug pipeline, could yield both robust income and capital appreciation, presenting a compelling investment opportunity.
See More
Pfizer's Stock Drops 50% Yet Remains Attractive for Investors
- Significant Stock Decline: Pfizer's stock has plummeted over 50% since its 2021 peak, primarily due to unmet expectations for COVID vaccine revenues, which has intensified market pessimism regarding its future prospects.
- High Dividend Appeal: Despite facing challenges, Pfizer currently offers a 6.5% dividend yield, providing a stable income source for long-term investors while also laying the groundwork for potential capital appreciation in the future.
- Drug Development Dynamics: Although Pfizer has fallen behind in the GLP-1 weight-loss drug race, it quickly pivoted by acquiring a company with a more promising drug candidate, demonstrating its agility in drug development and potential for future product launches.
- Management Confidence: Pfizer's management has clearly stated its intention to maintain the current dividend level despite pressures on profitability, indicating a commitment to shareholder returns while working to restore growth.
See More
S&P 500 Earnings Accelerate with Strong Performance
- Strong Earnings Performance: This week, over 125 S&P 500 companies reported earnings, with 110 exceeding EPS expectations and 103 showing year-over-year earnings growth, indicating resilience in corporate profitability amid changing economic conditions.
- AMD Leads Tech Sector: Advanced Micro Devices (AMD) reported robust revenue of $10.3 billion and an adjusted EPS of $1.37, driven by a 57% surge in Data Center sales, with a Q2 revenue outlook of $11.2 billion, highlighting strong demand in AI and data processing.
- Disney's Continued Growth: Disney (DIS) reported $25.17 billion in revenue and raised its annual EPS growth target to 12%, reflecting its sustained competitiveness and market demand in the entertainment and media sector.
- Super Micro's Optimistic Outlook: Super Micro Computer (SMCI) reported a challenging start with $10.2 billion in revenue, missing expectations, but significantly raised its 2026 revenue guidance to between $38.9 billion and $40.4 billion, indicating strong anticipated demand for AI computing infrastructure.
See More
